Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80
Glenmark Pharmaceuticals Limited
-(GLENMARK)
XNSE:GLENMARK, XBOM:GLENMARK
Glenmark Pharmaceuticals Ltd Q3FY24; 228% rise in Profits
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80
Glenmark Pharmaceuticals Ltd Q2FY24; 6% rise in Revenue
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80
Glenmark Pharmaceuticals Limited Q2 FY24 Earnings Conference Call Insights
Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q2 FY24 Earnings Concall Financial Results Revenue increased 6.3% YoY to INR35,879 million. India formulation
Glenmark Pharmaceuticals Ltd Q1FY24; 18% fall in Profits
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80
Glenmark Pharmaceuticals Limited Q4 FY23 Earnings Conference Call Insights
Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q4 FY23 Earnings Concall Q&A Highlights: [00:27:19] Tushar Manudhane at Motilal Oswal asked about the
Earnings Summary Of Glenmark Pharmaceuticals Limited For Q4 FY23
Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India. Established in 1977, the company has grown to become a
Glenmark Pharmaceuticals: An Uphill Battle
“Strategic priority is to enhance our free cash generation and further debt reduction and we continue discussion with potential partners for out-licensing
Earnings Summary Of Glenmark Pharmaceuticals Limited For Q3 FY23
Glenmark Pharmaceuticals Limited (NSE: GLENMARK) is a global research-driven pharmaceutical company that develops and markets innovative drugs for major therapeutic areas such
Glenmark Pharmaceuticals Limited (GLENMARK) Q3 FY23 Earnings Concall Transcript
Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Q3 FY23 Earnings Concall dated Feb. 13, 2023. Corporate Participants: Utkarsh Gandhi -- General Manager, Investor Relations Glenn Saldanha -- Chairman and
Glenmark Pharmaceuticals Limited (GLENMARK) Q2 FY23 Earnings Concall Transcript
Glenmark Pharmaceuticals Limited (NSE: GLENMARK) Q2 FY23 Earnings Concall dated Nov. 13, 2022 Corporate Participants: Utkarsh Gandhi -- General Manager - Investor Relations Brendan
Glenmark Pharmaceuticals Limited Q4 FY22 Earnings Conference Call Insights
https://youtu.be/uTUQ9VpSoiU Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q4 FY22 Earnings Concall Management Update: GLENMARK said the India business continues to significantly
Glenmark Pharmaceuticals Limited Q3 FY22 Earnings Conference Call Insights
https://www.youtube.com/watch?v=Mzpw87FqOBE Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q3 FY22 Earnings Concall Management Update: GLENMARK stated the India business continues to outperform